Novo Nordisk A/S

Eli Lilly and Company

The Danish pharma company also lowered its profit forecast for the third time this year

Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?

Danish pharmaceutical giant Novo Nordisk said its obesity drug Wegovy reduces cardiovascular risks more effectively than its main competitors. The company's shares jumped 3% as a result.

Best-selling Novo reduces heart risks more effectively than competitor, trial shows

The negative outlook for the company has already come true, an HSBC analyst thought

Wall Street's only bearish on Eli Lilly stock has changed its mind

By contrast, the shares of Eli Lilly's competitor, Ozempic manufacturer Novo Nordisk, fell 4%

Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose

Viking Therapeutics, Inc.

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Tesla, Inc.

Intel Corporation

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: foreign policy agenda remains in the center of attention of the markets

Wegovy is first-in-class approved for the treatment of liver disease, but its exclusivity is threatened by US-based Eli Lilly

Novo Nordisk shares rise after approval of Wegovy to treat liver disease

Meta Platforms, Inc.

Morning in New York: keeping a balance in the news flow

Bullish

Miami International Holdings, Inc.

Enterprise software developer Visma has begun preparations for an IPO that could be one of the largest in London in recent years. Shares of Bullish, a U.S. crypto exchange that competes with Binance and Coinbase, nearly doubled in debut trading. And in Hong Kong, retail investors helped Chinese rival Novo Nordisk triple its capitalization on the first day of trading. The main events on the IPO market during the week are in our selection.

Visma's listing in London and Bullish's success in New York: highlights of the IPO by August 17

In contrast, the securities of Eli Lilly's main competitor, Danish Novo Nordisk, rose in price by almost 7%


Eli Lilly has disappointed with the outcome of a weight loss pill trial. Shares are down 15%


Over the past year - from July 2024 to August 2025 - Novo Nordisk's stock, <a href="https://oninvest.com/issuers/novo-b-co">has lost</a> nearly 70% in value. That's a fantastic collapse for a company that makes sought-after diabetes and weight-loss drugs&nbsp; and is showing good revenue and profit growth. What happened to Novo Nordisk and how much of this investor reaction is justified?

The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created

LifeMD, Inc.

The small cap is still up almost 150% YTD